Bronchoconstriction and pulmonary hypertension during abortion induced by 15-methyl-prostaglandin F

E. Kenneth Weir, Benjamin E. Greer, Sidney C. Smith, Wayne Silvers, William Droegemueller, John T. Reeves, Robert F. Grover

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Patients have experienced severe breathlessness during second trimester abortion initiated by the intramuscular injection of 15-methyl-prostaglandin F (15-me-PGF). In four healthy women given 400 μg of 15-me-PGF to induce abortion, pulmonary function tests showed reductions in arterial oxygen tension, maximum expired air flow and vital capacity. Residual lung volume and the slope of phase III of the closing volume curves increased. These indications of marked peripheral bronchoconstriction persisted for more than 1 hour. In eight other women requesting abortion, initial pulmonary arterial pressures (11 ± 1 mm Hg) were less than normal (16 ± 1 mm Hg) suggesting that the lung vessels were dilated during pregnancy. The 15-me-PGF caused only a modest increase in pulmonary arterial and wedge pressures. Thus, bronchoconstriction rather than pulmonary circulatory changes probably caused the breathlessness observed in some patients. As an intramuscular abortifacient, 15-me-PGF has a widespread potential use, but it should not be given to patients with a history of asthma.

Original languageEnglish (US)
Pages (from-to)556-562
Number of pages7
JournalThe American Journal of Medicine
Issue number4
StatePublished - Apr 1976


Dive into the research topics of 'Bronchoconstriction and pulmonary hypertension during abortion induced by 15-methyl-prostaglandin F<sub>2α</sub>'. Together they form a unique fingerprint.

Cite this